Cannabidiol in the Treatment of Opioid Use Disorder
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Peak Plasma Concentration (Cmax)
研究概览
简要总结
The goal of the current study is to evaluate the bioavailability of CBD in normal healthy Individuals. This is an open cross-overdesign study in healthy individuals to assess the safety and pharmacokinetic (PK) effects of cannabidiol.
详细描述
The goal of this study is to determine the pharmacokinetics and pharmacodynamic profile of CBD in normal healthy individuals under standard and high fat fed conditions.
CBD has recently gained significant attention as a potential treatment for various disorders. One aspect for consideration in the development of CBD medication in capsule form is the poor bioavailability of cannabinoids such as CBD to obtain clinically effective doses since only ~4-6% of CBD is absorbed orally. This study will investigate the potential of CBD in a formulation in a capsule to enhance bioavailability, reduce the incidence of gastrointestinal side effects, reduce first pass metabolism and enhance onset time. This PK study will be conducted with standard meal and high fat conditions in normal healthy volunteers in a cross-over design, separated by a washout period of 1 week. Healthy volunteers are defined as having no significant health-related issues (i.e., the absence of significant medical, psychosocial, or emotional conditions) that are verified by clinical and psychiatric assessments.
The study will first evaluate in healthy volunteers the PK, tolerability and safety profiles of a new CBD formulation designed to improve bioavailability.
Test conditions and order:
- 200 mg CBD (standard meal)
- 400 mg CBD (standard meal)
- 400 mg Epidiolex (standard meal)
- 400 mg CBD (high fat meal)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Ability to understand and give informed consent;
- •Individuals between 18 and 65 years old; Sex is used a biological factor (50% of individuals recruited will be females, allowing sex comparisons).
- •English speakers.
- •Being healthy as determined by study physician according to screening medical and psychiatric history, physical examination, vitals, ECG and safety laboratory values. Only healthy volunteers with normal hepatic laboratory values will be enrolled.
- •Healthy volunteers who are medication- and drug-free, including free from nicotine and any prescribed medications.
排除标准
- •Having present or past medical conditions, including a DSM-5 Axis I psychiatric disorder, history of cardiac disease, arrhythmias, neurological disease of central origin, head trauma, and seizures
- •Using any psychoactive drug (other than nicotine) in at least the past 7 days (determined by lack of acute-opioid or other drugs related withdrawal symptoms and the negative result of a urine drug screen including an opioid drug metabolite test, and alcohol breathalyzer to detect alcohol intoxication);
- •Positive urine drug screen (cocaine, opiates, benzodiazepines, barbiturates, amphetamines, morphine, methadone, methamphetamines, oxycodone, phencyclidine, tricyclic antidepressant, tetrahydrocannabinol, buprenorphine, methylenedioxymethamphetamine, propoxyphene);
- •Having a history of hypersensitivity to cannabinoids or any of the ingredients in the product (gelatin and/or sesame oil);
- •Being pregnant or breastfeeding;
- •Not using an appropriate method of contraception such as hormonal contraception (oral hormonal contraceptives, Depo-Provera, Nuva-Ring), intrauterine device (IUD), sterilization, or double barrier method (combination of any two barrier methods used simultaneously, i.e. condom, spermicide, diaphragm);
- •Participating in another pharmacotherapeutic trial in the past 3 months;
- •History of impaired renal function or elevated liver enzymes at prescreening. The exclusionary lab values are: 3x nl AST/ALT, 1.5x bilirubin or 50%reduction in eGFR.
- •Participants who have used any medication, dietary supplements (and/or grape fruit juice), or combination of medications and supplements known to alter the metabolism of, or interact with CBD (bupropion, rifampin, barbiturates, phenothiazines, cimetidine, etc.) 14 days prior to and during the duration of the study.
研究组 & 干预措施
Standard Meal
Participants taking a standard meal.
干预措施: Cannabidiol 200mg (Drug)
Standard Meal
Participants taking a standard meal.
干预措施: Epidiolex (Drug)
Standard Meal
Participants taking a standard meal.
干预措施: Cannabidiol 400mg (Drug)
Standard Meal
Participants taking a standard meal.
干预措施: Placebo (Drug)
High Fat Meal
Participants taking a high fat meal.
干预措施: Cannabidiol 200mg (Drug)
High Fat Meal
Participants taking a high fat meal.
干预措施: Epidiolex (Drug)
High Fat Meal
Participants taking a high fat meal.
干预措施: Cannabidiol 400mg (Drug)
High Fat Meal
Participants taking a high fat meal.
干预措施: Placebo (Drug)
结局指标
主要结局
Peak Plasma Concentration (Cmax)
时间窗: up to 24 hours post-treatment
Peak plasma concentration of CBD and its metabolites
Systematic Assessment for Treatment Emergent Events (SAFTEE)
时间窗: up to 24 hours post-treatment
Systematic Assessment for Treatment Emergent Events (SAFTEE) to measure safety and adverse events.
Area under the plasma concentration curve (AUC)
时间窗: up to 24 hours post-treatment
Area under the plasma concentration versus time curve
次要结局
- Peak urine concentration of CBD (Umax)(up to 24 hours post-treatment)
- Area under the urine concentration curve (AUC)(up to 24 hours post-treatment)
研究者
Yasmin Hurd
Professor
Icahn School of Medicine at Mount Sinai